| Abstract |
Objective To analyze the effect of duloxetine combined with metformin in patients with diabetes and depression. Methods 91 patients with diabetes and depression and anxiety who came to our hospital from June 2017 to December 2018 were divided into 45 patients in the control group and 46 patients in the observation group according to the random number table. Both groups were given metformin orally. And psychological intervention, on this basis, the control group patients increased the oral treatment of venlafaxine, the observation group patients increased the dose of duloxetine oral treatment, observed two groups of patients after treatment neurotransmitter, cognitive function, plasma brain-derived nerve Nutritional factors, inflammatory factors, negative emotions of anxiety and depression, changes in cortisol levels, and the incidence of adverse reactions. Results The levels of NE, 5-HT, BDNF, NGF and WMS in the observation group were higher than those in the control group. The levels of TNF-α, cortisol, IL-6 and SDS and SAS were lower than those in the control group (P<0.05). There was no significant difference between the score and the control group (P>0.05). Conclusion Duloxetine can effectively improve the cognitive function of patients with diabetes and anxiety and depression, relieve anxiety and depression, and has high safety. The mechanism is related to the regulation of neurotransmitters, neurotrophic factors, cortisol levels and inhibition of inflammatory response.
|